SG11201804255QA - Treatment of intrahepatic cholestasis and related liver diseases - Google Patents
Treatment of intrahepatic cholestasis and related liver diseasesInfo
- Publication number
- SG11201804255QA SG11201804255QA SG11201804255QA SG11201804255QA SG11201804255QA SG 11201804255Q A SG11201804255Q A SG 11201804255QA SG 11201804255Q A SG11201804255Q A SG 11201804255QA SG 11201804255Q A SG11201804255Q A SG 11201804255QA SG 11201804255Q A SG11201804255Q A SG 11201804255QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- intrahepatic cholestasis
- pct
- subject
- publication
- Prior art date
Links
- 208000001024 intrahepatic cholestasis Diseases 0.000 title abstract 4
- 230000007872 intrahepatic cholestasis Effects 0.000 title abstract 4
- 208000019423 liver disease Diseases 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 239000003613 bile acid Substances 0.000 abstract 1
- 238000006345 epimerization reaction Methods 0.000 abstract 1
- 230000007062 hydrolysis Effects 0.000 abstract 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562266771P | 2015-12-14 | 2015-12-14 | |
| PCT/EP2016/080941 WO2017102816A1 (en) | 2015-12-14 | 2016-12-14 | Treatment of intrahepatic cholestasis and related liver diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804255QA true SG11201804255QA (en) | 2018-06-28 |
Family
ID=57570064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804255QA SG11201804255QA (en) | 2015-12-14 | 2016-12-14 | Treatment of intrahepatic cholestasis and related liver diseases |
Country Status (16)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8906668B2 (en) | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| AU2013347805C1 (en) | 2012-11-23 | 2018-06-28 | Seres Therapeutics, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| HK1220326A1 (zh) | 2013-03-15 | 2017-05-05 | Seres Therapeutics, Inc. | 基於网络微生物组成和方法 |
| EP4529950A3 (en) | 2014-10-31 | 2025-08-20 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment |
| KR102680943B1 (ko) | 2017-08-14 | 2024-07-03 | 세레스 테라퓨틱스, 인코포레이티드 | 담즙정체성 질환 치료를 위한 조성물 및 방법 |
| CA3073838A1 (en) | 2017-08-30 | 2019-03-07 | Pendulum Therapeutics, Inc. | Methods and compositions for treatment of microbiome-associated disorders |
| CN111432826A (zh) | 2017-10-30 | 2020-07-17 | 赛里斯治疗公司 | 用于治疗抗生素耐药性的组合物和方法 |
| AU2019306649A1 (en) | 2018-07-19 | 2021-02-04 | Pendulum Therapeutics, Inc. | Methods and compositions for microbial engraftment |
| CN113728088B (zh) | 2018-09-13 | 2025-02-14 | 未知君有限责任公司 | 治疗胃肠障碍和炎性障碍的方法和组合物 |
| CN112280720B (zh) * | 2020-11-19 | 2021-07-13 | 山东龙昌动物保健品有限公司 | 一株多形拟杆菌gl-02及其与胆汁酸复配的复合菌剂与应用 |
| WO2023176951A1 (ja) | 2022-03-18 | 2023-09-21 | 株式会社明治 | Ｃｏｌｌｉｎｓｅｌｌａ属細菌の増殖制御用組成物及びその利用 |
| GB2628547A (en) * | 2023-03-27 | 2024-10-02 | Univ Newcastle | Probiotic and postbiotic compositions, products and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1283225B1 (it) * | 1996-03-11 | 1998-04-16 | Renata Maria Anna Ve Cavaliere | Ceppi di batteri, composizione farmaceutica contenente uno o piu' di tali ceppi e uso dei medesimi per la prevenzione e la terapia delle |
| AU4905300A (en) * | 1999-05-25 | 2000-12-12 | Andrew W. Bruce | Oral administration of lactobacillus for the maintenance of health in women |
| AUPQ899700A0 (en) * | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| MY148872A (en) * | 2006-02-15 | 2013-06-14 | Nestec Sa | Use of bifidobacterium longum for the prevention and treatment of inflammation |
| WO2010125421A1 (en) * | 2009-04-30 | 2010-11-04 | Compagnie Gervais Danone | Use of collinsella aerofaciens for reducing bloating |
| CN102539791A (zh) * | 2012-01-09 | 2012-07-04 | 宁波天康生物科技有限公司 | 总胆汁酸的定量测定及测定试剂盒 |
| AU2014331610B2 (en) * | 2013-10-03 | 2019-11-07 | Trustees Of The University Of Pennsylvania | Compositions comprising a defined microbiome and methods of use thereof |
-
2016
- 2016-12-14 RU RU2018124487A patent/RU2743405C2/ru active
- 2016-12-14 US US15/781,595 patent/US20180369297A1/en not_active Abandoned
- 2016-12-14 ES ES16812728T patent/ES2962302T3/es active Active
- 2016-12-14 BR BR112018012022-7A patent/BR112018012022A2/pt not_active IP Right Cessation
- 2016-12-14 WO PCT/EP2016/080941 patent/WO2017102816A1/en active Application Filing
- 2016-12-14 CN CN201680073160.6A patent/CN109069548A/zh active Pending
- 2016-12-14 SG SG11201804255QA patent/SG11201804255QA/en unknown
- 2016-12-14 JP JP2018530858A patent/JP2018537484A/ja active Pending
- 2016-12-14 EP EP16812728.0A patent/EP3389680B1/en active Active
- 2016-12-14 MX MX2018007227A patent/MX2018007227A/es unknown
- 2016-12-14 IL IL259480A patent/IL259480B2/en unknown
- 2016-12-14 AU AU2016374365A patent/AU2016374365B2/en not_active Expired - Fee Related
- 2016-12-14 CA CA3008195A patent/CA3008195A1/en active Pending
- 2016-12-14 KR KR1020187019268A patent/KR20180094950A/ko not_active Ceased
-
2018
- 2018-06-11 CL CL2018001548A patent/CL2018001548A1/es unknown
- 2018-07-12 ZA ZA2018/04660A patent/ZA201804660B/en unknown
-
2022
- 2022-07-28 JP JP2022120558A patent/JP2022166039A/ja not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL259480B1 (en) | 2023-05-01 |
| KR20180094950A (ko) | 2018-08-24 |
| WO2017102816A1 (en) | 2017-06-22 |
| ZA201804660B (en) | 2022-12-21 |
| IL259480A (en) | 2018-07-31 |
| CA3008195A1 (en) | 2017-06-22 |
| US20180369297A1 (en) | 2018-12-27 |
| CN109069548A (zh) | 2018-12-21 |
| MX2018007227A (es) | 2018-08-01 |
| AU2016374365B2 (en) | 2023-04-13 |
| EP3389680C0 (en) | 2023-10-11 |
| RU2018124487A (ru) | 2020-01-10 |
| JP2018537484A (ja) | 2018-12-20 |
| BR112018012022A2 (pt) | 2018-12-04 |
| AU2016374365A1 (en) | 2018-07-12 |
| JP2022166039A (ja) | 2022-11-01 |
| EP3389680A1 (en) | 2018-10-24 |
| RU2018124487A3 (enrdf_load_stackoverflow) | 2020-05-29 |
| IL259480B2 (en) | 2023-09-01 |
| RU2743405C2 (ru) | 2021-02-18 |
| EP3389680B1 (en) | 2023-10-11 |
| CL2018001548A1 (es) | 2018-07-20 |
| ES2962302T3 (es) | 2024-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804255QA (en) | Treatment of intrahepatic cholestasis and related liver diseases | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201909325RA (en) | 2-amino-quinoline derivatives | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201810048VA (en) | Tri-segmented pichinde viruses as vaccine vectors | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201900910TA (en) | RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201804312RA (en) | Microbubble-chemotherapeutic agent complex for sonodynamic therapy | |
| SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
| SG11201805649UA (en) | Therapeutic anti-cd9 antibody | |
| SG11201804577RA (en) | Fgf21 variants | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201900021PA (en) | Methods and compositions for the treatment of cancer | |
| SG11201901374WA (en) | Antibiotic compounds | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201808592PA (en) | Method for selection of high m6p recombinant proteins | |
| SG11201804965SA (en) | Augmented acid alpha-glucosidase for the treatment of pompe disease | |
| SG11201807977XA (en) | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor | |
| SG11201908393YA (en) | Modulators of pcsk9 expression |